Myocarditis Acute
18
7
7
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
17%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (18)
One-year Prognostic Impact of Microcirculation Assessed by NH IMR Angio in Patients Hospitalized for Acute Myocarditis
Arrhythmic Risk in Myocarditis Outcome Research
Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis
French Registry of CMR Late Gadolinium Enhancement in Myocarditis
Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital
Abatacept in Immune Checkpoint Inhibitor Myocarditis
MYTHS - MYocarditis THerapy With Steroids
CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance
Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort
Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis
Ventricular Arrhythmia After Myocarditis in Sportsman
Role of Spectral CT in the Diagnosis of Myocarditis/MINOCA in Patients Undergoing cardioCT Investigations for Acute Chest Pain
Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics
MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study
Multicenter Retrospective Observational Study of Acute Myocarditis in Korea
Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis
Evaluation of Long-term Incidence of Ventricular Arrhythmias in Patients With Acute Myocarditis
Analysis of Cardiac Damage Post Infection With SARS-CoV-2 and Post Vaccination Against COVID-19